Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Company Overview - Dianthus Therapeutics is currently experiencing a transformative period, highlighted by significant advancements in their clinical data for myasthenia gravis, a neuromuscular condition, which has been positively received by investors [4]. Product Development - The company has in-licensed a promising product, referred to as 212, from Leads Bio in China. This product is characterized as a potential best-in-class bifunctional fusion protein that targets BDCA2 to reduce Type 1 interferon and BAFF/APRIL [4]. - Preliminary results indicate that this product may demonstrate greater potency than Litifilimab, which is part of Biogen's portfolio and is currently being studied for systemic lupus erythematosus (SLE) [4].